Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Publication | Closed Access

DOI

373

Citations

References

2018

Year

Gerd R Burmester, Joel M. Kremer, Filip Van den Bosch, Alan Kivitz, Louis Bessette, Yihan Li, Yijie Zhou, Mohamed I. A. Othman, Aileen L. Pangan, Heidi S. Camp

The Lancet

Rheumatoid DisorderRheumatologyTranslational MedicineAnti-inflammatoryPlacebo-controlled Phase 3Rheumatic DiseasesPharmacologyClinical TrialsInflammatory Rheumatic DiseasePharmacotherapyMedicineRheumatoid ArthritisInadequate Response